Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
National Law Review

Billion-Dollar Verdict Overturned: Trial Court’s Refusal of Non-Standard Jury Instruction Proves Fatal

On Dec. 22, 2025, a three-judge panel of the Superior Court of Pennsylvania, in a non-precedential opinion, vacated a highly publicized $1 billion jury verdict against Mitsubishi from 2023. The ...
Forbes

You’re Not Learning From Failure. You’re Explaining It Away.

Leaders think they drive accountability. Their teams disagree. The gap reveals how explanation replaces investigation—and why failures keep repeating. Your team ...
Hosted on MSN

Indians and their cultural inferiority complex, explains Romila Thapar

NAMIT: While the Hindutva world view is driven by a small cadre of ideologues who weaponize religion for political gain, it now resonates widely with middle-class Hindus. They respond enthusiastically ...